980 Shares in Chemed Corporation $CHE Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. purchased a new stake in Chemed Corporation (NYSE:CHE) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 980 shares of the company’s stock, valued at approximately $495,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Chemed in the 2nd quarter valued at $34,000. Versant Capital Management Inc raised its stake in Chemed by 7,500.0% during the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock worth $35,000 after acquiring an additional 75 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new stake in Chemed during the 2nd quarter worth $36,000. MassMutual Private Wealth & Trust FSB lifted its position in Chemed by 65.3% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock valued at $38,000 after acquiring an additional 32 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in Chemed in the second quarter valued at $49,000. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Chemed

In other Chemed news, Director Patrick P. Grace sold 190 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the completion of the sale, the director directly owned 3,533 shares of the company’s stock, valued at $1,879,556. This represents a 5.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $513.45, for a total value of $1,026,900.00. Following the sale, the chief executive officer directly owned 66,418 shares of the company’s stock, valued at $34,102,322.10. The trade was a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 9,190 shares of company stock worth $4,833,160. Company insiders own 3.33% of the company’s stock.

Chemed Stock Down 0.1%

CHE stock opened at $512.24 on Tuesday. The company has a market cap of $6.69 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 2.06 and a beta of 0.51. The company has a fifty day moving average price of $514.82 and a 200 day moving average price of $461.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. Chemed Corporation has a 12 month low of $365.20 and a 12 month high of $557.00.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.60 by $0.46. The company had revenue of $673.25 million for the quarter, compared to the consensus estimate of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. Chemed’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the firm posted $4.27 EPS. Sell-side analysts expect that Chemed Corporation will post 23.55 earnings per share for the current year.

Chemed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 0.5%. This is a positive change from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. Chemed’s payout ratio is currently 14.06%.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Royal Bank Of Canada lifted their target price on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 30th. Oppenheimer upped their target price on Chemed from $500.00 to $590.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Weiss Ratings raised Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Bank of America restated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Finally, UBS Group began coverage on Chemed in a research report on Friday, September 25th. They set a “buy” rating and a $650.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $554.60.

Chemed Profile

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.